Page last updated: 2024-11-12
n-coumaroyldopamine
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
N-coumaroyldopamine: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 11630793 |
| CHEMBL ID | 2296788 |
| SCHEMBL ID | 24305785 |
| MeSH ID | M0492853 |
Synonyms (22)
| Synonym |
|---|
| (e)-n-[2-(3,4-dihydroxyphenyl)ethyl]-3-(4-hydroxyphenyl)prop-2-enamide |
| AKOS016012349 |
| (e)-n-(3,4-dihydroxyphenethyl)-3-(4-hydroxyphenyl)acrylamide |
| 103188-46-1 |
| CHEMBL2296788 |
| AC-26417 |
| DTXSID50469749 |
| AS-72648 |
| (2e)-n-[2-(3,4-dihydroxyphenyl)ethyl]-3-(4-hydroxyphenyl)prop-2-enamide |
| mfcd17129089 |
| trans-4-coumaroyldopamine |
| unii-hbc0y4wz56 |
| (2e)-n-(2-(3,4-dihydroxyphenyl)ethyl)-3-(4-hydroxyphenyl)-2-propenamide |
| n-p-coumaroyldopamine |
| hbc0y4wz56 , |
| n-coumaroyldopamine |
| p-coumaroyldopamine |
| (e)-n-(2-(3,4-dihydroxyphenyl)ethyl)-3-(4-hydroxyphenyl)-2-propenamide |
| A921482 |
| C71135 |
| CS-0186104 |
| SCHEMBL24305785 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (5)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1293689 | Uncompetitive inhibition of baker's yeast alpha-glucosidase using pNPG as substrate by Cornish-Bowden plot analysis | 2016 | European journal of medicinal chemistry, May-23, Volume: 114 | Cinnamic acid amides from Tribulus terrestris displaying uncompetitive α-glucosidase inhibition. |
| AID1428456 | Antioxidant activity assessed as DPPH radical scavenging activity incubated for 30 mins | 2016 | Journal of natural products, Dec-23, Volume: 79, Issue:12 | Antioxidant Flavonols and Phenolic Compounds from Atraphaxis frutescens and Their Inhibitory Activities against Insect Phenoloxidase and Mushroom Tyrosinase. |
| AID1293688 | Inhibition of baker's yeast alpha-glucosidase using pNPG as substrate by spectrophotometry | 2016 | European journal of medicinal chemistry, May-23, Volume: 114 | Cinnamic acid amides from Tribulus terrestris displaying uncompetitive α-glucosidase inhibition. |
| AID1428457 | Inhibition of Acyrthosiphon pisum phenoloxidase using L-DOPA as substrate preincubated for 5 mins followed by substrate addition measured after 120 to 240 mins by spectrophotometric method | 2016 | Journal of natural products, Dec-23, Volume: 79, Issue:12 | Antioxidant Flavonols and Phenolic Compounds from Atraphaxis frutescens and Their Inhibitory Activities against Insect Phenoloxidase and Mushroom Tyrosinase. |
| AID1428458 | Inhibition of mushroom tyrosinase using L-DOPA as substrate preincubated for 5 mins followed by substrate addition measured for 10 mins by spectrophotometric method | 2016 | Journal of natural products, Dec-23, Volume: 79, Issue:12 | Antioxidant Flavonols and Phenolic Compounds from Atraphaxis frutescens and Their Inhibitory Activities against Insect Phenoloxidase and Mushroom Tyrosinase. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (5)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 26.99
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (26.99) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||